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Abstract
Objective—Structural brain imaging studies in Obsessive-Compulsive Disorder (OCD) have 
produced inconsistent findings. This may be partially due to limited statistical power from 
relatively small samples and clinical heterogeneity related to variation in disease profile and 
developmental stage.
Methods—To address these limitations, we conducted a meta- and mega-analysis of data from 
OCD sites worldwide. T1 images from 1,830 OCD patients and 1,759 controls were analyzed, 
using coordinated and standardized processing, to identify subcortical brain volumes that differ in 
OCD patients and healthy controls. We additionally examined potential modulating effects of 
clinical characteristics on morphological differences in OCD patients.
Results—The meta-analysis indicated that adult patients had significantly smaller hippocampal 
volumes (Cohen’s d=−0.13; p=5.1x10−3, % difference −2.80) and larger pallidum volumes 
(d=0.16; p=1.6x10−3, % difference 3.16) compared to adult controls. Both effects were stronger in 
medicated patients compared to controls (d=−0.29; p=2.4x10−5, % difference −4.18 and d=0.29; 
p=1.2x10−5, % difference 4.38, respectively). Unmedicated pediatric patients had larger thalamic 
volumes (d=0.38, p=2.1x10−3) compared to pediatric controls. None of these findings were 
mediated by sample characteristics such as mean age or field strength. Overall the mega-analysis 
yielded similar results.
Conclusion—Our study indicates a different pattern of subcortical abnormalities in pediatric 
versus adult OCD patients. The pallidum and hippocampus seem to be of importance in adult 
OCD, whereas the thalamus seems to be key in pediatric OCD. This highlights the potential 
importance of neurodevelopmental alterations in OCD, and suggests that further research on 
neuroplasticity in OCD may be useful.
Introduction
Obsessive-compulsive disorder (OCD) is a neurodevelopmental disorder that affects 1–3% 
of the population (1; 2). In more than 50% of all OCD cases, symptoms emerge during 
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childhood or adolescence (1; 3), and in more than 40% of these cases the disorder persists 
into adulthood (4). OCD symptoms have been associated with structural and functional brain 
abnormalities in the parallel cortico-striato-thalamo-cortical circuits and other related brain 
networks, involving fronto-parietal, fronto-limbic and cerebellar regions (5; 6).
Several studies have shown volumetric abnormalities in different deep grey matter 
structures, mainly the basal ganglia (7–10). Meta-analyses have repeatedly, although not 
consistently, reported larger volumes in the lenticular nucleus extending to the caudate (11–
14). In addition, Pujol et al. (7) showed that the relative enlargement of striatal areas in OCD 
patients was driven by an older age of the subject and a longer disease duration, suggesting 
that basal ganglia alterations progress throughout the disease course, supported by the mega-
analysis from the OCD Brain Imaging Consortium (OBIC) (15). These findings led to the 
hypothesis that preservation of basal ganglia volume resulted from neuroplastic changes due 
to chronic compulsivity.
Although these findings suggest ongoing neuroplasticity, a lifespan approach has seldom 
been used to understand the variation in structural abnormalities in OCD (5). Studying the 
brain characteristics of disease during childhood may minimize the potentially confounding 
effects of neuroplastic changes associated with chronic symptomatology and long-term 
treatment. Pediatric studies have been sparse and small, leaving the extant findings 
inconclusive and variable. For example, some studies reported increased thalamus volume in 
adult (16; 17) and pediatric OCD patients (18), supported by two meta-analyses (14; 19) 
showing larger thalamus volumes in OCD patients when pediatric and adult data were 
combined. In contrast, several recent meta-analyses showed no differences in thalamus 
volumes while combining adult and pediatric subjects (11–13). The variation across studies 
may partially be explained by variations in the developmental and disease stages of the 
subjects included.
In view of the clinical heterogeneity of OCD, relatively small samples, differences in data 
acquisition, data processing protocols, and statistical analyses further contribute to the 
inconsistent findings. Different segmentation algorithms may give variable estimates of 
subcortical volumes and thus their sensitivity to regionalized group differences (20). To 
overcome the heterogeneity in image processing and to increase sample sizes, especially 
regarding pediatric data, we initiated the OCD Working-Group within the Enhancing 
NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium (21).
The ENIGMA-OCD Working-Group is an international collaboration and its current aim is 
to identify subcortical imaging markers that differ in OCD patients and healthy controls, 
both in children and in adults. Therefore, we conducted a meta- and mega-analysis on 
structural Magnetic Resonance Imaging (MRI) data of 1,830 OCD patients and 1,759 
healthy controls. The mega-analysis ensures information preservation and enables the 
examination of specific effects of demographic and clinical parameters. By employing meta- 
and mega-analysis we sought to investigate whether the mega-analytical design has greater 
sensitivity to detect more subtle brain abnormalities from increased statistical power.
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In this study, we investigated nine regions of interest (i.e. seven subcortical grey matter 
regions, lateral ventricle, and total intracranial volume) in OCD patients compared to healthy 
controls by performing the largest meta- and mega-analysis to date. In additional exploratory 
analyses, we examined potential modulating effects of demographic, clinical, and 
methodological characteristics on subcortical brain volume in OCD. Based on previous 
meta- and mega-analyses, we expected subcortical brain volumes to vary across 
developmental stage showing differences between pediatric and adult OCD, and disease 
profile and stage, including co-morbidity.
Methods
Samples
The ENIGMA-OCD Working-Group includes 35 datasets from 25 international research 
institutes, with neuroimaging and clinical data from OCD patients and controls, including 
both children and adults. We considered subjects ≥18 years as adults and subjects <18 years 
as children. Since previous literature suggested differential effects between pediatric and 
adult samples, we performed separate meta- and mega-analysis for adult and pediatric data. 
Demographics and clinical characteristics of the participants in each center are shown in 
Tables 1 and 2, respectively. In total, we analyzed data from 3,589 subjects including 1,830 
OCD patients (N=335 children, N=1,495 adults) and 1,759 controls (N=287 children, 
N=1,472 adults). All local IRBs permitted the use of extracted measures of the completely 
anonymized data.
Image acquisition and processing
Structural T1-weighted MRI brain scans were acquired and analyzed locally. Images were 
acquired at different field strengths (i.e., 1.5T and 3T). The acquisition parameters of each 
sample are listed in Supplementary Table 1. The images were analyzed using the fully 
automated and validated segmentation software FreeSurfer v5.3. (22) following standardized 
protocols to harmonize analysis and quality control processes across multiple sites (http://
enigma.ini.usc.edu/protocols/imaging-protocols/). Segmentation of nine regions of interest, 
including seven subcortical grey matter structures, i.e., nucleus accumbens, amygdala, 
caudate, hippocampus, pallidum, putamen, and thalamus, the lateral ventricle volumes 
(mean bilateral and right and left side separately), and total intracranial volume were 
visually inspected for accuracy (Supplementary Information 2).
Meta-analysis of subcortical brain volumes
We examined differences between OCD patients and controls across samples by performing 
a meta-analysis on the mean of the left and right hemisphere measures of each subcortical 
structure. The meta-analysis was based on multiple linear regression models, with the mean 
subcortical brain volume as the outcome measure and a binary indicator of diagnosis 
(0=controls, 1=patients) as the predictor of interest. All models were controlled for age, sex, 
and intracranial volume. Effect size estimates, adjusted for age, sex, and intracranial volume, 
were calculated using Cohen’s d-metric computed from the t-statistic of the diagnosis 
indicator variable from the regression models.
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To explore the influence of sex and age on between-group subcortical volume differences, 
we assessed the significance of diagnosis-by-sex and diagnosis-by-age interaction effects 
within each sample. Further, multiple linear regression models were used to investigate the 
within-group effects of age at onset, disease duration, disease severity (using the Yale-Brown 
Obsessive-Compulsive Scale (Y-BOCS) and the Children’s Y-BOCS (23; 24) total severity 
score) as continuous variables. To further study the neurodevelopmental aspects of disease 
within the adult samples, we performed separate stratified meta-analyses comparing early-
onset OCD patients (<18 years) to controls, and late-onset OCD patients (≥ 18 years) to 
controls. Stratified meta-analyses were also performed for medicated and non-medicated 
patients. Likewise separate stratified analyses were performed to investigate comorbid major 
depressive disorder (MDD), comorbid anxiety disorders, and OCD symptom dimensions 
(using the Y-BOCS symptom checklist; Supplementary Information 5 symptom dimension 
analyses).
All regression models and effect size estimates were fit at each site separately. Subsequently, 
a final Cohen’s d-effect size estimate was obtained using an inverse variance-weighted 
random-effect meta-analysis model with the R package ‘metaphor’ (version 1.9-118). The 
meta-analysis of disease severity, age at onset, and disease duration were exceptions. The 
scores on these variables were considered as continuous variables, so effect sizes are 
reported using Pearson’s r, a partial-correlation after removing nuisance variables (age, sex, 
and intracranial volume). The final meta-analyzed Pearson’s r was estimated following the 
same inverse variance-weighted random-effect meta-analysis models used for the other 
meta-analyses (Supplementary Information 3).
Moderator analyses
Meta-regressions were performed to examine the effects of moderator variables on meta-
analysis effect sizes. We tested whether hypothesized moderating factors such as the mean 
age of each sample, field strength, percentage of patients taking antidepressants and 
percentage of patients taking antipsychotics influenced the effect size estimates of the OCD 
patients versus controls comparison of all subcortical volumes across samples included in 
the meta-analysis. Each moderator variable was separately included as a fixed effect 
predictor in a meta-regression model. We report uncorrected P-values with a significance 
threshold determined by Bonferroni correction for testing nine regions of interest 
(P=0.05/9= 5.6×10−3).
Power Analysis
Sample sizes that achieve 80% power to detect group differences given the presented effect 
sizes were calculated based two-sided t-tests assuming unequal variance with G*Power 
v3.2.1. (25). See Supplementary Information 4 for full details of the power analysis.
Mega-analysis of subcortical brain volumes
We also performed a mega-analysis by pooling all volumetric measurements. The mega-
analysis of each mean ((left+right)/2) subcortical volume was performed using the following 
model: Brain volume= βageXage+ βsexXsex+ βintracranial volumeXintracranial volume+ 
βdiagnosisXdiagnosis+ βcohort1Xcohort1+….+ βcohort35Xcohort35+ ε. Similar to the meta-analysis, 
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several covariates of interest were investigated using this regression model. Results were 
considered significant if they exceeded the Bonferroni corrected P-value threshold 5.6×10−3.
Results
We included data of 25 adult cohorts and 10 pediatric cohorts. The adult meta- and mega-
analysis contained 1,495 OCD patients and 1,472 controls and the pediatric meta- and mega-
analysis contained 335 OCD patients and 287 controls. An overview of the number of 
participants included per cohort is given in Table 1. Supplementary Information 5 describes 
which sites were included in the analyses regarding the clinical characteristics, and what was 
considered a sufficient amount of data.
Meta-analysis
OCD patients versus healthy controls
Adult comparison—Results from the analysis comparing all adult OCD patients 
(N=1,495) to all adult controls (N=1,472) across nine regions of interest volumes are 
provided in Figure 1a and Table 3. Compared to controls, adult OCD patients showed 
significantly smaller hippocampal volume (Cohen’s d [95% confidence interval]: d=−0.13 
[−0.23, −0.04]; P-value= 5.08×10−3, % difference −2.80) and larger pallidum volume (d=
+0.16 [0.06, 0.26]; P-value= 1.60×10−3, % difference 3.16). No significant diagnosis-by-sex 
or diagnosis-by-age interaction effect for any of the subcortical volumes was observed.
Pediatric comparison—None of the subcortical volumes was significantly different 
between pediatric OCD cases (N=335) and controls (N=287) after Bonferroni correction 
(Supplementary Table 2).
Influence of medication on subcortical volume
Adult comparisons—Compared to controls, medicated OCD patients (N=654) showed 
larger lateral ventricles (d=+0.24 [0.08, 0.41]; P-value= 2.95×10−3, % difference 2.97) and a 
larger pallidum volume (d= +0.29 [0.16, 0.42]; P-value= 1.20×10−5, % difference 4.38) as 
well as a smaller hippocampal volume (d=− 0.29 [−0.43, −0.16]; P-value= 2.39×10−5, % 
difference −4.18). We did not detect any significant differences between unmedicated OCD 
patients (N=821) and healthy controls, nor between medicated OCD patients and 
unmedicated OCD patients. See Supplementary Table 3a–c for full meta-analytic details 
regarding medication influence on the adult comparisons.
Pediatric comparisons—Figure 1b and Table 4 show that the unmedicated pediatric 
OCD patients (N=159), compared with controls, had larger thalamic volume (d= +0.38 
[0.14, 0.63]; P-value= 2.09×10−3, % difference 3.08). Further, we found smaller nucleus 
accumbens volume in medicated pediatric OCD patients (N=170) compared with controls 
(d= −0.32 [−0.54, −0.09]; P-value= 5.25×10−3, % difference −2.79). No significant 
differences were detected between medicated and unmedicated pediatric OCD patients 
(Supplementary Table 4a–b).
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Influence of comorbid MDD on subcortical volume in adult OCD
Adult comparisons—Supplementary Table 5a–c shows that compared to controls, OCD 
patients with a comorbid lifetime diagnosis of depression (N=325) had smaller hippocampal 
volume (d=−0.27 [−0.43, −0.12]; P-value= 6.43×10−4, % difference −3.41) and larger lateral 
ventricles (d= +0.29 [0.14, 0.44]; P-value= 1.16×10−4, % difference 3.85). OCD patients 
without a comorbid lifetime diagnosis of MDD (N=1,041) present larger pallidum volume 
(d=+0.19 [0.09, 0.29]; P-value= 1.56×10−4, % difference 3.78) and smaller hippocampal 
volume (d=−0.16 [−0.25, −0.06]; P-value= 1.04×10−3, % difference −3.28). No significant 
subcortical volume differences were observed between OCD patients with and without a 
comorbid lifetime depression.
Pediatric comparisons—Too few pediatric samples had sufficient numbers of subjects 
with MDD to permit analyses (Supplementary Information 5).
Influence of a comorbid anxiety disorder on subcortical volume
Adult comparisons—Compared to controls, patients without a comorbid anxiety 
diagnosis (N=1002) showed bigger pallidum volume (d= +0.17 [0.05, 0.28]; P-value= 
4.70×10−3, % difference 2.83) and smaller hippocampal volume (d= −0.20 [−0.30, −0.10]; 
P-value= 1.51×10−4, % difference −3.79). We did not detect any significant differences 
between OCD patients with a comorbid anxiety diagnosis (N=291) and controls. The 
comparison between OCD patients with and without a comorbid anxiety diagnosis showed 
that OCD patients with a comorbid lifetime anxiety diagnosis had larger intracranial volume 
(d= +0.41 [0.12, 0.70]; P-value= 5.08×10−3, % difference 2.80) (Supplementary Table 6a–c).
Pediatric comparisons—Too few pediatric samples had sufficient numbers of subjects 
with comorbid anxiety disorders to permit analyses (Supplementary Information 5).
Influence of symptom dimensions on subcortical volume
Adult comparisons—Regression analyses within OCD patients on symptom dimensions 
(N=1,151) showed no association of the presence of a particular symptom dimension and 
volume of any of the subcortical volumes.
Pediatric comparisons—Insufficient data on the symptom dimensions was available to 
perform meta-analyses (Supplementary Information 5).
Influence of age of onset and disease duration on subcortical volume
Stratified analyses (Supplementary Table 7a–c) show that adult OCD patients with an early 
disease-onset (N=626) exhibited larger pallidum volumes (d=+0.25 [0.12, 0.38]; P-value= 
2.30×10−4, % difference 3.68) and that patients with a late disease-onset (N=794) exhibited 
smaller hippocampal volume (d=−0.18 [−0.29, −0.08]; P-value= 7.87×10−4, % difference 
−3.36) than controls. No significant differences in subcortical brain volume were found 
when comparing early onset with late-onset adult OCD patients. In addition, we did not 
observe any significant association between age of onset nor disease duration - as continuous 
variables - and subcortical volumes in the adult (N=1420) nor pediatric (N=285) OCD group 
(Supplementary Table 8a–b and 9a–b).
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Association of disease severity with subcortical volumes
We did not detect any significant associations, neither in adult (N=1,455) nor in pediatric 
(N=328) OCD patients, between disease severity and subcortical volumes (Supplementary 
Table 10 and 11).
Moderator analyses
Mean age of each sample and field strength did not moderate case-control differences in 
subcortical volumes in the adult or pediatric meta-analysis. The percentage of patients using 
an SSRI or antipsychotic medication of each adult sample did not moderate the subcortical 
volume differences (Supplementary 12 and 13).
Mega-analysis
Adult OCD
Results of the adult mega-analysis are shown in Supplementary Table 14. Overall the results 
of the mega-analysis yielded similar results as the meta-analysis. The case-control mega-
analysis indicated a larger pallidum volume (β=0.06; P-value= 1.02×10−4) and smaller 
hippocampal volume (β=−0.05; P-value= 4.66×10−4). The pallidum (β=0.09; P-value= 
5.50×10−7) and hippocampus (β=−0.09; P-value= 1.99×10−7) effects were more pronounced 
in the comparison between medicated OCD patients and controls. Early-onset patients 
showed larger pallidum volumes (β=0.08; P-value= 8.42×10−6) than controls. Patients with a 
late disease-onset (β=−0.06; P-value= 8.23×10−5) and patients with a comorbid depression 
(β=−0.07; P-value= 2.75×10−4) presented smaller hippocampal volumes compared to 
controls.
Pediatric OCD
Results of the pediatric mega-analysis are shown in Supplementary Table 15. Pediatric OCD 
patients, compared with controls, have a larger thalamus volume (β=0.08; P-value= 
5.47×10−3). The thalamic effect was more pronounced in patients without a comorbid 
anxiety disorder (β=0.11; P-value= 9.60×10−4) and in patients without a comorbid 
depression (β=0.09; P-value= 2.16×10−3).
Discussion
This worldwide collaborative analysis identified distinct subcortical volume alterations in 
pediatric and adult OCD. The adult meta- and mega-analyses were consistent and results 
showed that, compared with controls, adult OCD patients had significantly smaller 
hippocampal and larger pallidum volumes. Both findings were more pronounced in the 
subsample of medicated OCD patients versus controls. Furthermore, the smaller 
hippocampal volume seemed to be driven, at least partly, by the OCD patients with 
comorbid depression and late disease-onset. Indeed jackknife resampling showed a robust 
pallidum effect and a hippocampal effect dependent on site characteristics (data not shown). 
The larger pallidum finding was more pronounced in the adult OCD patients with an early 
disease-onset. The pediatric mega-analysis showed larger thalamus in OCD based on the 
main group comparison, whereas the meta-analysis only showed this in unmedicated 
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pediatric OCD patients compared with controls. The pediatric mega-analysis also suggests 
that larger thalamic volume in pediatric OCD patients is specific to those without comorbid 
anxiety or depression. The finding of a larger thalamic volume in pediatric OCD is in line 
with some previous research in pediatric OCD patients (18; 26). Notably, Gilbert et al. (18) 
suggested a normalizing effect of pharmacological treatments on thalamic volume in 
pediatric OCD. The current adult meta- and mega-analyses did not reveal group differences 
in thalamic volume, consistent with the most recent meta-analyses of OCD (11–13). The 
only meta-analytic findings of thalamic enlargement in OCD included pediatric patients (14; 
19). These results provide evidence of a clear distinction in thalamic volume across pediatric 
and adult OCD, and suggest that an increased thalamic volume may be an early marker of 
the disease, unrelated to disease severity, and may be related to altered neurodevelopment. 
Indeed, patients with other neurodevelopmental disorders such as Tourette’s syndrome (27) 
and ADHD (28), also present a morphologically enlarged thalamus.
Most previous research (11; 13–15; 19) did not report volumetric differences in the 
hippocampal complex of OCD patients. The (para)hippocampal regions are specifically 
vulnerable to stress-related toxic changes (29). Greater volume loss in these regions may 
thus be related to chronic stress and the exaggerated emotional responsiveness seen in OCD 
(30). The hippocampal effect in OCD patients was more pronounced in medicated patients 
and seemed to be driven, at least partly, by the OCD patients with a comorbid major 
depression (31). These two findings are probably not independent, since patients with 
comorbidities are often the patients who receive medication. Further, Selles et al (32) 
showed that a comorbid depression is associated with a late-onset of the disease. This is in 
line with our finding that the hippocampal effect seemed to be driven by late-onset OCD 
patients. Other ENIGMA disease working-groups, such as those focusing on MDD (33), 
schizophrenia (34), and bipolar disorder (35), also observed smaller hippocampal volume in 
patients, which suggests that the hippocampal abnormalities in OCD are disease non-
specific, and possibly related to chronic stress and comorbid depression.
Our results suggest a key role for the pallidum in adult OCD patients. Prior meta-analyses 
have reported greater lenticular (i.e., putamen and pallidum) volume in OCD patients (11–
14). On the contrary patients with other anxiety disorders showed decreased lenticular 
nucleus volume (13). Since repetitive behaviors differentiate OCD from other anxiety 
disorders, the increased lenticular volume in OCD may reflect these unique symptoms (13). 
Our analyses also suggested that the early-onset adult OCD patients drive the pallidum 
effect. We, therefore, hypothesize that a larger pallidum in OCD patients could be the 
consequence of disease chronicity. Notably, the ENIGMA-schizophrenia (34) Working-
Group also observed a larger pallidum in schizophrenia patients compared to controls. 
Future ENIGMA research will enable cross-diagnosis analyses to further investigate 
common and distinct neural substrates across psychiatric disease groups.
Our analyses could not replicate findings of increased putamen and caudate nucleus volumes 
observed in smaller meta-analyses (11–14). Note that, these studies used different 
segmentation techniques. One may argue that the technique might influence findings in case 
of adjacent structures such as the pallidum and putamen (36). Our current observations 
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suggest that subcortical alterations in adult OCD may be limited to the pallidum and 
hippocampus rather than widespread.
This study constitutes the largest meta- and mega-analysis of subcortical brain volumes in 
OCD to date. Strengths of this study include the sample size (N=3,589) and inclusion of 
both adults and children. Another strength is our strategy that ensured great methodological 
homogeneity by standardizing brain segmentation techniques and statistical models across 
all participating samples, which increased the power to detect small effects. A similar 
strategy has been used in parallel by other ENIGMA working-groups (33–35). This method 
generates highly significant findings and allows us to systematically investigate the effects of 
clinical characteristics on brain alterations in OCD patients.
This study also had limitations. First, a recent study showed effects of workstation vendor 
and operating system version on brain volume and cortical thickness estimates (37). Indeed 
the individual sites did differ in operating system and workstation vendor. Additionally, 
Schoemaker et al. 2016 showed that FreeSurfer tends to overestimate subcortical volumes in 
children (38). However, this non-systematic error probably affects patients and controls 
equally. Second, although we have pooled an enormous amount of data, subjects with 
comorbidities and subjects categorized to each specific symptom dimension especially in the 
pediatric datasets were still limited. However, the key variable, i.e., the CY-BOCS score, the 
gold standard clinical instrument in pediatric OCD research, was present in all subjects. 
Third, the structure labelled as “thalamus” by FreeSurfer’s segmentation algorithm may 
contain both white matter and grey matter. We, therefore, cannot conclude that this thalamic 
enlargement involves grey matter enlargement solely. Fourth, our findings indicate 
medication effects. It should be noted, however, that only current medication status has been 
taken into consideration. It is difficult to attribute the results to direct effects of the 
medication itself. Furthermore, the range of medications that are generally prescribed to 
OCD patients is very broad. Although we have tested whether different types of medication 
influenced our findings, we were not able to calculate relative doses of different medication 
types and analyze medication effects in a more fine-grained fashion due to the retrospective 
nature of our study. Thus we need to interpret these findings with caution.
Despite these limitations, results of this first initiative of the ENIGMA-OCD Working-
Group clearly indicate a key role of the thalamus and pallidum in the pathophysiology of 
pediatric and adult OCD, respectively. Our findings suggest a different pattern of subcortical 
abnormalities in pediatric and adult OCD patients, which is in line with the developmental 
nature of OCD and neuroplastic changes during the course of the disease. The current study 
is a first step toward identifying robust brain volume alterations in OCD patients. An 
important next step is to apply similar methods in order to identify robust cortical imaging 
markers on cortical thickness and surface area measures associated with OCD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Cohen’s d-effect sizes 95% CI for differences in subcortical brain volumes between adult 
OCD patients and healthy controls. (b) Cohen’s d-effect sizes 95% CI for differences in 
subcortical brain volumes between unmedicated pediatric OCD patients and pediatric 
healthy controls. Effect sizes were corrected for age, sex, and intracranial volume.
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